PK Accelerator Bundled Solution Accelerates Pharmacokinetic Analysis and
MOUNTAIN VIEW, Calif., June 24 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it will be launching PK Accelerator (PKA(TM)), a system of bundled software coupled with a rapid deployment service provided at a fixed price and fixed scope. Adopting PK Accelerator will allow small to mid-sized organizations to deploy Pharsight's "best practices" solution for end-to-end pharmacokinetic analysis and validatable CFR 21 part 11 reporting in as little as 90 days.
Small to mid-sized research oriented pharmaceutical and biotech
companies deploying PK Accelerator will be able to take advantage of the
operational efficiencies Pharsight's enterprise and desktop software
packages were designed to deliver. The software components of the PKA
bundle will consist of the Pharsight(R) Knowledgebase Server(TM) (PKS),
WinNonlin(R) Autopilot(TM), PKS Reporter(TM), the PKS and WinNonlin
Validation Suites(TM), upgrades to WinNonlin Enterprise, and a choice of
two of the following database connectors: Watson(TM), Excel(TM), or CDISC.
All of these components have been designed for seamless interoperability
and will be implemented as a complete system with minimal configuration. PK
Accelerator will bring state-of-the-art clinical pharmacology archiving,
analysis, and reporting capabilities within reach of smaller firms by
standardizing the system's training and deployment procedures and
leveraging Pharsight's best practices recommendations for system
configuration and implementation.
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved